NCT03784391View on ClinicalTrials.gov

Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina

CompletedOBSERVATIONAL
Enrollment

3,000

Participants

Timeline

Start Date

December 14, 2018

Primary Completion Date

April 6, 2020

Study Completion Date

April 6, 2020

Conditions
Chagas' Disease
Interventions
DRUG

Lampit (Nifurtimox, BAYA2502)

Nifurtimox is a drug already approved in some South American countries since more than 45 years

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY